Payment overview · 2025
General Payments
$7,434.37
108 reported records · 14 companies
Healthcare provider profile · identity verified
Binusha Moitheennazima, MD
Allopathic & Osteopathic Physicians|Internal Medicine · NACOGDOCHES, TX · NPI 1760658330
Verified facts
What the public records show
CMS Open Payments records show Binusha Moitheennazima, MD received $7,434.37 in general payments during 2025 across 108 reported records.
AstraZeneca Pharmaceuticals LP accounted for 77.3% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 19 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Nucala, Ofev, Trelegy Ellipta.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BEVESPI AEROSPHERE as an associated drug or biological on 763 records involving 473 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Bevespi Aerosphere by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 41 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 274 claims for Symbicort by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Jardiance by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported OFEV as an associated drug or biological on 14236 records involving 6873 distinct recipient NPIs. Public Medicare Part D data also shows 30 claims for Ofev by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NUCALA as an associated drug or biological on 100127 records involving 16970 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Nucala by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 540 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Jardiance by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $5,744.75 | 77.3% | 23 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $529.44 | 7.1% | 25 | 2025 |
| Verona Pharma, Inc. | Unresolved — no canonical attribution shown | $310.51 | 4.2% | 29 | 2025 |
| JAZZ PHARMACEUTICALS INC. | Unresolved — no canonical attribution shown | $193.18 | 2.6% | 5 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $164.36 | 2.2% | 7 | 2025 |
| Viatris Specialty LLC | Unresolved — no canonical attribution shown | $97.72 | 1.3% | 4 | 2025 |
| Inspire Medical Systems, Inc. | Unresolved — no canonical attribution shown | $91.99 | 1.2% | 2 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $86.82 | 1.2% | 4 | 2025 |
| ARS Pharmaceuticals Operations, Inc. | Unresolved — no canonical attribution shown | $53.51 | 0.7% | 2 | 2025 |
| Insmed, Inc. | Unresolved — no canonical attribution shown | $48.14 | 0.7% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $41.33 | 0.6% | 2 | 2025 |
| Philips North America LLC | Unresolved — no canonical attribution shown | $25.62 | 0.3% | 1 | 2025 |
| Regeneron Healthcare Solutions, Inc. | Unresolved — no canonical attribution shown | $24.27 | 0.3% | 1 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $22.73 | 0.3% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Consulting Fee | $5,076.00 | 3 |
| Food and Beverage | $2,234.38 | 103 |
| Education | $123.99 | 2 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $2,219.49 | 14 | 2025 |
Source payment records
|
|||||
| FASENRA Normalized: fasenra |
Biological | AstraZeneca Pharmaceuticals LP | $1,779.84 | 2 | 2025 |
Source payment records
|
|||||
| Ohtuvayre Normalized: ohtuvayre |
Drug | Verona Pharma, Inc. | $310.51 | 29 | 2025 |
Source payment records
|
|||||
| NUCALA Normalized: nucala |
Biological | GlaxoSmithKline, LLC. | $304.82 | 13 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $224.62 | 12 | 2025 |
Source payment records
|
|||||
| XYWAV Normalized: xywav |
Drug | JAZZ PHARMACEUTICALS INC. | $193.18 | 5 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $154.46 | 5 | 2025 |
Source payment records
|
|||||
| TEZSPIRE Normalized: tezspire |
Biological | Amgen Inc., AstraZeneca Pharmaceuticals LP | $127.46 | 6 | 2025 |
Source payment records
|
|||||
| OFEV Normalized: ofev |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $101.45 | 4 | 2025 |
Source payment records
|
|||||
| YUPELRI Normalized: yupelri |
Drug | Viatris Specialty LLC | $97.72 | 4 | 2025 |
Source payment records
|
|||||
| INSPIRE Normalized: inspire |
Device | Inspire Medical Systems, Inc. | $91.99 | 2 | 2025 |
Source payment records
|
|||||
| NEFFY Normalized: neffy |
Drug | ARS Pharmaceuticals Operations, Inc. | $53.51 | 2 | 2025 |
Source payment records
|
|||||
| Arikayce Normalized: arikayce |
Drug | Insmed, Inc. | $48.14 | 2 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $41.33 | 2 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $36.52 | 2 | 2025 |
Source payment records
|
|||||
| Vest Therapy Und Normalized: vest therapy und |
Device | Philips North America LLC | $25.62 | 1 | 2025 |
Source payment records
|
|||||
| JASCAYD Normalized: jascayd |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $24.83 | 1 | 2025 |
Source payment records
|
|||||
| DUPIXENT Normalized: dupixent |
Biological | Regeneron Healthcare Solutions, Inc. | $24.27 | 1 | 2025 |
Source payment records
|
|||||
| WINREVAIR Normalized: winrevair |
Biological | Merck Sharp & Dohme LLC | $22.73 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| NUCALA nucala |
2025 | Nucala | 2024 | 14 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| OFEV ofev |
2025 | Ofev | 2024 | 30 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 540 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BEVESPI AEROSPHERE open payments reported associated product |
CMS Open Payments — General Payments 763 supporting records · 473 recipient NPIs · example record 1206131384 |
Bevespi Aerosphere · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
41 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
274 | 84 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | OFEV open payments reported associated product |
CMS Open Payments — General Payments 14236 supporting records · 6873 recipient NPIs · example record 1221811762 |
Ofev · 2024 Exact normalized brand match · 1 Part D row |
30 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | NUCALA open payments reported associated product |
CMS Open Payments — General Payments 100127 supporting records · 16970 recipient NPIs · example record 1190332378 |
Nucala · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
540 | 149 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Montelukast Sodium | Montelukast Sodium | 2134 | 547 |
| Fluticasone Propionate | Fluticasone Propionate | 775 | 290 |
| Prednisone | Prednisone | 624 | 319 |
| Atorvastatin Calcium | Atorvastatin Calcium | 564 | 58 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 540 | 149 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 496 | 244 |
| Furosemide | Furosemide | 420 | 68 |
| Potassium Chloride | Potassium Chloride | 370 | 58 |
| Trazodone Hcl | Trazodone Hcl | 370 | 74 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 322 | 88 |
| Amlodipine Besylate | Amlodipine Besylate | 316 | 39 |
| Levothyroxine Sodium | Levothyroxine Sodium | 310 | 44 |
| Gabapentin | Gabapentin | 297 | 36 |
| Eliquis | Apixaban | 293 | 30 |
| Advair Hfa | Fluticasone Propion/Salmeterol | 284 | 92 |
| Symbicort | Budesonide/Formoterol Fumarate | 274 | 84 |
| Sertraline Hcl | Sertraline Hcl | 239 | 21 |
| Breo Ellipta | Fluticasone/Vilanterol | 227 | 53 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 227 | 69 |
| Ventolin Hfa | Albuterol Sulfate | 217 | 92 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 215 | 166 |
| Pantoprazole Sodium | Pantoprazole Sodium | 210 | 39 |
| Mirtazapine | Mirtazapine | 168 | 19 |
| Escitalopram Oxalate | Escitalopram Oxalate | 159 | 18 |
| Losartan Potassium | Losartan Potassium | 157 | 19 |
| Tamsulosin Hcl | Tamsulosin Hcl | 152 | 14 |
| Omeprazole | Omeprazole | 134 | 35 |
| Azelastine Hcl | Azelastine Hcl | 133 | 50 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 131 | 18 |
| Buspirone Hcl | Buspirone Hcl | 128 | 25 |
| Zolpidem Tartrate | Zolpidem Tartrate | 126 | 26 |
| Metoprolol Succinate | Metoprolol Succinate | 116 | 18 |
| Ropinirole Hcl | Ropinirole Hcl | 116 | 23 |
| Azithromycin | Azithromycin | 115 | 89 |
| Famotidine | Famotidine | 113 | 24 |
| Baclofen | Baclofen | 111 | 13 |
| Clopidogrel | Clopidogrel Bisulfate | 108 | 14 |
| Citalopram Hbr | Citalopram Hydrobromide | 103 | suppressed |
| Levetiracetam | Levetiracetam | 103 | suppressed |
| Allopurinol | Allopurinol | 101 | 19 |
| Spiriva Respimat | Tiotropium Bromide | 101 | 23 |
| Budesonide | Budesonide | 99 | 14 |
| Paroxetine Hcl | Paroxetine Hcl | 99 | suppressed |
| Spironolactone | Spironolactone | 99 | 16 |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 98 | 40 |
| Doxycycline Hyclate | Doxycycline Hyclate | 98 | 76 |
| Sucralfate | Sucralfate | 92 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 87 | suppressed |
| Januvia | Sitagliptin Phosphate | 86 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 85 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 85 | suppressed |
| Lisinopril | Lisinopril | 83 | 13 |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 81 | 26 |
| Xarelto | Rivaroxaban | 80 | suppressed |
| Clonazepam | Clonazepam | 79 | 13 |
| Levofloxacin | Levofloxacin | 77 | 51 |
| Myrbetriq | Mirabegron | 77 | suppressed |
| Pregabalin | Pregabalin | 75 | suppressed |
| Roflumilast | Roflumilast | 75 | 22 |
| Digoxin | Digoxin | 74 | suppressed |
| Finasteride | Finasteride | 71 | suppressed |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 71 | suppressed |
| Primidone | Primidone | 70 | suppressed |
| Simvastatin | Simvastatin | 70 | suppressed |
| Carvedilol | Carvedilol | 69 | 13 |
| Nystop | Nystatin | 67 | 23 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 66 | 25 |
| Oseltamivir Phosphate | Oseltamivir Phosphate | 62 | 59 |
| Divalproex Sodium | Divalproex Sodium | 61 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 60 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 58 | 11 |
| Memantine Hcl | Memantine Hcl | 58 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 58 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 57 | 12 |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 56 | 19 |
| Spiriva Handihaler | Tiotropium Bromide | 55 | 20 |
| Cefdinir | Cefdinir | 53 | 40 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 52 | suppressed |
| Arnuity Ellipta | Fluticasone Furoate | 50 | 17 |
| Epinephrine | Epinephrine | 50 | 43 |
| Metoprolol Tartrate | Metoprolol Tartrate | 47 | 11 |
| Entresto | Sacubitril/Valsartan | 46 | suppressed |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 46 | 15 |
| Metformin Hcl | Metformin Hcl | 44 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 43 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 43 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 42 | 16 |
| Metolazone | Metolazone | 42 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 41 | suppressed |
| Aripiprazole | Aripiprazole | 40 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 40 | suppressed |
| Temazepam | Temazepam | 40 | 13 |
| Valproic Acid | Valproic Acid (As Sodium Salt) | 40 | suppressed |
| Insulin Syringe | Syringe-Needle,insulin,0.5 Ml | 39 | 23 |
| Mometasone Furoate | Mometasone Furoate | 38 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 38 | 28 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 36 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 36 | 14 |
| Amiodarone Hcl | Amiodarone Hcl | 35 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 35 | suppressed |
| Fluconazole | Fluconazole | 35 | 23 |
| Gemtesa | Vibegron | 35 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 34 | suppressed |
| Hydrochlorothiazide | Hydrochlorothiazide | 34 | suppressed |
| Meloxicam | Meloxicam | 33 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 33 | suppressed |
| Breyna | Budesonide/Formoterol Fumarate | 32 | 17 |
| Hydralazine Hcl | Hydralazine Hcl | 32 | suppressed |
| Levalbuterol Hcl | Levalbuterol Hcl | 31 | suppressed |
| Nystatin | Nystatin | 30 | 15 |
| Ofev | Nintedanib Esylate | 30 | suppressed |
| Topiramate | Topiramate | 29 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 29 | suppressed |
| Alprazolam | Alprazolam | 28 | suppressed |
| Cilostazol | Cilostazol | 28 | suppressed |
| Ibuprofen | Ibuprofen | 28 | suppressed |
| Phenobarbital | Phenobarbital | 28 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 27 | 14 |
| Ezetimibe | Ezetimibe | 27 | suppressed |
| Sodium Chloride | 0.9 % Sodium Chloride | 27 | suppressed |
| Bupropion Xl | Bupropion Hcl | 26 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 26 | suppressed |
| Enoxaparin Sodium | Enoxaparin Sodium | 26 | suppressed |
| Torsemide | Torsemide | 26 | suppressed |
| Autoshield Duo Pen Needle | Pen Needle,dual Safety,diabetc | 25 | suppressed |
| Bevespi Aerosphere | Glycopyrrolate/Formoterol Fum | 24 | suppressed |
| Bumetanide | Bumetanide | 24 | suppressed |
| Cyclosporine | Cyclosporine | 24 | suppressed |
| Latanoprost | Latanoprost | 24 | suppressed |
| Rivastigmine | Rivastigmine Tartrate | 24 | suppressed |
| Nifedipine Er | Nifedipine | 23 | suppressed |
| Nuedexta | Dextromethorphan Hbr/Quinidine | 23 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 22 | suppressed |
| Ingrezza | Valbenazine Tosylate | 22 | suppressed |
| Fluticasone-Salmeterol Hfa | Fluticasone Propion/Salmeterol | 21 | 17 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 21 | suppressed |
| Carbamazepine | Carbamazepine | 20 | suppressed |
| Celecoxib | Celecoxib | 20 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 20 | suppressed |
| Dulera | Mometasone/Formoterol | 20 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 20 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 19 | suppressed |
| Methocarbamol | Methocarbamol | 19 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 19 | suppressed |
| Amantadine | Amantadine Hcl | 18 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 18 | suppressed |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 18 | suppressed |
| Calcitriol | Calcitriol | 17 | suppressed |
| Fasenra Pen | Benralizumab | 17 | suppressed |
| Ketoconazole | Ketoconazole | 17 | suppressed |
| Ozempic | Semaglutide | 17 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 17 | 17 |
| Albuterol Sulfate | Albuterol Sulfate | 16 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 16 | suppressed |
| Tiotropium Bromide | Tiotropium Bromide | 16 | suppressed |
| Zemaira | Alpha-1-Proteinase Inhibitor | 16 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 15 | suppressed |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 15 | 15 |
| Fluticasone Propionate Hfa | Fluticasone Propionate | 15 | suppressed |
| Olanzapine | Olanzapine | 15 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 15 | suppressed |
| Icosapent Ethyl | Icosapent Ethyl | 14 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 14 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 14 | suppressed |
| Linzess | Linaclotide | 14 | suppressed |
| Nucala | Mepolizumab | 14 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 13 | suppressed |
| Cephalexin | Cephalexin | 13 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 13 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 13 | suppressed |
| Ondansetron Odt | Ondansetron | 13 | suppressed |
| Risperidone | Risperidone | 13 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 12 | suppressed |
| Glimepiride | Glimepiride | 12 | suppressed |
| Jardiance | Empagliflozin | 12 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 12 | suppressed |
| Triazolam | Triazolam | 12 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 12 | suppressed |
| Armodafinil | Armodafinil | 11 | suppressed |
| Hydrocortisone | Hydrocortisone | 11 | suppressed |
| Levalbuterol Tartrate Hfa | Levalbuterol Tartrate | 11 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 11 | suppressed |
| Novolin R | Insulin Regular, Human | 11 | suppressed |
| Ranolazine Er | Ranolazine | 11 | suppressed |
| Ziprasidone Hcl | Ziprasidone Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $7,434.37 · 108 records | AstraZeneca Pharmaceuticals LP | AIRSUPRA, AREXVY, Arikayce, BREZTRI, DUPIXENT, FASENRA, INSPIRE, JASCAYD, NEFFY, NUCALA, OFEV, Ohtuvayre, TEZSPIRE, TRELEGY ELLIPTA, Vest Therapy Und, WINREVAIR, XYWAV, YUPELRI, ZEPBOUND | 8 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Nucala play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error